Wisconsin Doctor Regains DEA Registration After Exclusion Hearing Victory
Published Date: 10/17/2025
Notice
Summary
Shannon Wagner, D.O., from Green Bay, Wisconsin, applied for a DEA registration but was initially denied because she was excluded from federal health programs like Medicare and Medicaid. After a hearing, the judge recommended approving her application, and the DEA agreed, allowing her to move forward. This decision affects Dr. Wagner’s ability to legally handle controlled substances and participate in federal programs, clearing the way for her professional activities without financial penalties.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Granted to Physician
The DEA dismissed the Order to Show Cause and granted Shannon Wagner, D.O. a DEA Certificate of Registration (Control No. W23130415C). The order was signed October 1, 2025 and is effective immediately, allowing Dr. Wagner to legally seek duties that require a DEA registration (for example, positions in corrections that require such registration).
Mandatory Federal Exclusion Remains In Effect
The record shows Shannon Wagner was mandatorily excluded from Medicare, Medicaid, and all federal health care programs effective December 18, 2014 for a minimum period of thirteen years, with that exclusion ending in 2027. The Agency found she has been, and continues to be, excluded under 42 U.S.C. 1320a-7(a).
Ongoing Restitution Obligation Continues
Dr. Wagner has paid, and continues to pay, ordered restitution of $270,000 and has been making monthly payments of $150. She testified she will increase payments once she obtains higher paying employment.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
Previous / Next Documents
Previous: 2025-19576, Grace S. Joanita, N.P.; Decision and Order
Grace S. Joanita, a nurse practitioner from Ohio, lost her DEA registration because she lied on her renewal application. She didn’t respond to the government’s warnings or ask for a hearing, so her registration was officially revoked. This means she can no longer legally handle controlled substances, effective immediately.
Next: 2025-19578, Hovic Pharmacy; Decision and Order
Hovic Pharmacy in Houston lost its DEA license because it filled many controlled substance prescriptions in ways that didn’t follow pharmacy rules, risking drug abuse and illegal distribution. This decision means Hovic can no longer legally handle these drugs, protecting public safety. The change is effective immediately, impacting the pharmacy’s business and its customers.